Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.

MLA

Clarke, N. W., et al. “Addition of Docetaxel to Hormonal Therapy in Low- and High-Burden Metastatic Hormone Sensitive Prostate Cancer: Long-Term Survival Results from the STAMPEDE Trial.” Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 30, no. 12, Dec. 2019, pp. 1992–2003. EBSCOhost, https://doi.org/10.1093/annonc/mdz396.

APA

Clarke, N. W., Ali, A., Ingleby, F. C., Hoyle, A., Amos, C. L., Attard, G., Brawley, C. D., Calvert, J., Chowdhury, S., Cook, A., Cross, W., Dearnaley, D. P., Douis, H., Gilbert, D., Gillessen, S., Jones, R. J., Langley, R. E., MacNair, A., Malik, Z., … James, N. D. (2019). Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 30(12), 1992–2003. https://doi.org/10.1093/annonc/mdz396

Chicago

Clarke, N W, A Ali, F C Ingleby, A Hoyle, C L Amos, G Attard, C D Brawley, et al. 2019. “Addition of Docetaxel to Hormonal Therapy in Low- and High-Burden Metastatic Hormone Sensitive Prostate Cancer: Long-Term Survival Results from the STAMPEDE Trial.” Annals of Oncology : Official Journal of the European Society for Medical Oncology 30 (12): 1992–2003. doi:10.1093/annonc/mdz396.